I think this UK small-cap stock is just getting started

This UK small-cap stock has caught my eye. The shares have been rising but I think there’s further potential. Here’s why.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’ve come across a UK small-cap stock, Sensyne Health (LSE: SENS) and reckon it has lots of potential. The shares have been rising on the back on recent positive news. 

I think the company is just getting started and I’d buy the stock in my portfolio. Here’s why.

Sensyne Health: what does it do?

In a nutshell, Sensyne Health is an AIM-listed healthcare company that uses artificial intelligence to analyse data. The company operates two divisions — Discovery Sciences and Software Products.

I’ll explain each of these businesses in turn.

Discovery Sciences

I should highlight that over 80% of revenue is generated from the Discovery Sciences division. This is where it analyses anonymised patient data from NHS trusts using machine learning (a subset of artificial intelligence). So I like the stock because the analysis can be used to improve pharmaceutical development, increase the understanding of diseases and advance clinical design trials.

One reason I’m excited about this UK small-cap stock is that this division bridges the gap between the NHS and the pharmaceutical industry. The NHS has been busy converting its paper files into digital records. And in my opinion, the NHS has the data but has limited resources to analyse it. Pharmaceutical companies are likely to welcome a company that has already done the number crunching and can offer both scientific value and a financial return.

Software Products

While the Software Products business is small, I think it has huge growth potential. Sensyne Health develops digital health products that help clinicians with patient care. These digital products also generate data, which the company can use for research.

I think division is a key growth driver. Some of Sensyne Health’s products enable clinicians to remotely monitor and manage diabetes and blood pressure during pregnancy. I reckon if this is successful, these products could be rolled out to the wider patient community, thereby increasing revenue potential.

I also like that the firm is collecting data from its products. This means that it’ll be able to analyse it and sell the scientific value it creates to pharmaceutical companies.

The risks

While I feel this small-cap stock has lots of potential, there are still risks involved. Sensyne Health is generating revenue but is loss-making. It’s using cash for research and development of its products, which for now is eating into its profitability.

I think this is likely to continue for the foreseeable future and may impact Sensyne Health shares.

There’s also no guarantee its products will be successful. And any delays or negative news are likely to hit the stock price.

Recent developments

There’s been a recent flurry of positive news that has lifted the shares though. Sensyne Health has signed an exclusive license with Excalibur Healthcare Services. It will use its MagnifEye software product with Excalibur’s rapid diagnostic tests, which includes its Covid-19 antigen test. To me there’s growth potential for Sensyne because the test has been approved by the UK regulator for mass population screening in symptomatic and asymptomatic people.

The firm also announced that its SYNE-COV machine learning algorithm for Covid risk prediction has achieved regulatory approval in the UK. I think this is a milestone for the company. I’d buy the stock and reckon things are only getting started for Sensyne Health.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Nadia Yaqub has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could I use a stock market crash to turn £20k into half a mil in just over a decade?

A stock market crash might sound terrifying to some but it can also present a once-in-a-lifetime opportunity to accumulate generational…

Read more »

Investing Articles

Recently released: October’s small-cap stock recommendation [PREMIUM PICKS]

We believe the UK small-cap market offers a myriad of opportunities across a wide range of different businesses and industries.

Read more »

Investing Articles

Here’s how a Stocks and Shares ISA and Lifetime ISA could supercharge my wealth!

Individual Savings Accounts (ISAs) can help UK share investors take their earnings to the next level. And their importance is…

Read more »

A person holding onto a fan of twenty pound notes
Investing Articles

A high-yield dividend ETF and an investment trust to consider this November!

Investors wanting to boost their passive income could benefit from investigating these high-yield funds and trusts, says Royston Wild.

Read more »

Investing Articles

2 of my favourite, cheap FTSE 100 growth shares this November!

These FTSE 100 growth shares could be great long-term picks to consider, reckons Royston Wild. At current prices he thinks…

Read more »

Investing Articles

Up 26%, can the BT share price really push higher still?

The BT share price has surged on several catalysts in 2024, but there’s evidence to suggest that the stock could…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

What are the best dividend shares to buy right now?

As shares in B&M European Value Retail have fallen, the dividend yield has reached a 10-year high. Should investors be…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

My favourite FTSE 100 passive income stock that keeps the Christmas coffers full

The holiday season is expensive and can leave many consumers struggling to make ends meet. Here’s how I use a…

Read more »